It is necessary to determine whether psoriasis responds to methotrexate in the same manner in patients with and without psoriatic arthritis.
P soriasis is a chronic, immune-mediated inflammatory skin disease caused by the interaction of multiple susceptibility genes and environmental factors that affects 1% to 3% of the population worldwide. 1 The prevalence of psoriasis in China is 0.47%. 2 Systemic agents available for psoriasis treatment include conventional agents, such as acitretin, cyclosporine, and methotrexate; targeted smallmolecule drugs (apremilast); and biologic agents that target distinct proinflammatory cytokines. 3 Biologics and smallmolecule drugs are more expensive compared with conventional drugs, which limits their widespread use, especially in developing countries. Less than 10% of patients with psoriasis receive biologic agents routinely, even in high-income countries. 4 Methotrexate is a folate antagonist 5 with anti-inflammatory properties. [6] [7] [8] [9] Methotrexate has been used as a first-line treatment for moderate to severe psoriasis for more than 50 years. 10 We undertook a prospective, single-center, observational study to assess the effectiveness, tolerability, hematotoxicity, and hepatotoxicity of oral methotrexate for the treatment of patients with psoriasis without and with psoriatic arthritis. To our knowledge, a prospective, comparative study of the efficacy and adverse effects of methotrexate in Chinese patients with psoriasis with and without psoriatic arthritis has not yet been performed.
Methods

Study Population and Study Design
This single-center, prospective, single-arm, interventional study was performed at the Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China, from April 1, 2015, to December 31, 2017. Patients 18 years or older were recruited from the outpatient population. Only patients with moderate to severe psoriasis with or without psoriatic arthritis were included in this study. Patients who received therapy with UV light, methotrexate, or other systemic treatments for psoriasis or arthropathy within 1 month of study initiation were excluded. Topical treatments were stopped 1 week before the start of the methotrexate treatment. The European guidelines on contraindications and restrictions on methotrexate use were followed. 11 The
Medical Ethics Committee of Huashan Hospital, Fudan University, reviewed and approved the protocol, and all patients provided written informed consent. All data were deidentified.
Treatment
The initial oral methotrexate dose was 7.5 to 10 mg once weekly. The dose was increased by 2.5 mg every 2 to 4 weeks to a maximum of 15 mg weekly depending on the patient's clinical response and adverse effects and results of routine hematologic and blood chemistry tests. Folic acid supplementation was not recommended because it is not available in our clinics. If liver enzyme level elevations were more than 2-fold or less than 3-fold, the methotrexate dose was reduced by 2.5 mg weekly and administered once 2 to 4 weeks later. If the liver enzyme level elevations were more than 3-fold, methotrexate treatment was stopped.
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Effectiveness and Tolerability Assessments
Two certified dermatologists graded the severity and extent of psoriasis using the Psoriasis Area Severity Index (PASI) and body surface area (BSA) scores and tabulated the adverse events. Psoriatic arthritis was assessed using the Classification Criteria for the Study of Psoriatic Arthritis (CASPAR). 13 Complete blood cell counts, liver enzyme levels, and renal function were measured at baseline and at weeks 4, 8, and 12.
Statistical Analysis
The data are expressed as means (SDs). The statistical analyses were performed using unpaired t tests, Mann-Whitney tests, unpaired t tests with Welch correction, 1-way analyses of variance with repeated measures, χ 2 tests, or Fisher exact tests, as appropriate. Multiple test correction was conducted using the Benjamini-Hochberg procedure. Data analyses were performed using GraphPad Prism software, version 5 (GraphPad Software Inc). P < .05 was considered to be statistically significant. 
Results
Disease Duration and Likelihood of Having Diabetes
Key Points
Question What are the differences in effectiveness and safety of methotrexate for patients with psoriasis with and without psoriatic arthritis?
Findings In this Chinese cohort study of 107 patients with psoriasis without arthritis and 128 patients with psoriasis with psoriatic arthritis who were undergoing methotrexate therapy, the 90% reduction from baseline Psoriasis Area Severity Index response was significantly lower in the patients with psoriatic arthritis than in the patients without arthritis. In addition, methotrexate-induced adverse events occurred more often in the patients with psoriatic arthritis than in those without psoriatic arthritis.
Meaning Methotrexate may be more effective and may have fewer adverse effects in patients with psoriasis without concomitant psoriatic arthritis.
Using the CASPAR criteria, 128 patients (54.5%) were diagnosed with psoriatic arthritis. Patients with psoriatic arthritis had a longer duration of psoriasis before entering the study. Furthermore, a significantly higher proportion of patients with psoriatic arthritis had diabetes compared with the 107 patients without psoriatic arthritis. [11.6] years; P = .02) was significantly longer in patients with psoriatic arthritis ( Table 1 ). The number of male patients, body mass index (BMI) (calculated as weight in kilograms divided by height in meters squared), baseline PASI, BSA score, 50% reduction from baseline PASI score (PASI50), 75% reduction from baseline PASI score (PASI75), mean PASI changes at weeks 8 and 12, incidence of hypertension, and proportions of patients who smoked and consumed alcohol did not differ between the patients with and without psoriatic arthritis.
Effectiveness of Methotrexate in Patients With and Without Psoriatic Arthritis
As indicated in Table 2 , the 90% reduction from baseline PASI score (PASI90) response rates were significantly higher in patients without psoriatic arthritis compared with those with psoriatic arthritis at week 8 (12 [ Methotrexate Treatment-Associated Adverse Events 
Association of Increased Liver Enzyme Levels in Patients With Psoriasis With Smoking and BMI
Fifteen patients with psoriatic arthritis (11.7%) and 15 patients without psoriatic arthritis (14.0%) had elevated ALT levels before they received methotrexate. Consequently, the patients were divided into 3 groups: group 1, patients whose ALT levels were normal before and after treatment; group 2, patients whose ALT levels were elevated before methotrexate treatment; and group 3, patients who experienced methotrexate-associated ALT level elevations. Methotrexate-associated elevation of ALT level was associated with body mass index (mean [SD] body mass index, 26 [4] in the patients with psoriatic arthritis [P = .04] and 26 [4] in b One-way analyses of variance and χ 2 test were used to compare elevation groups with normal group. Multiple test correction was conducted using Benjamini-Hochberg procedure. P < .05 is considered to be statistically significant.
Discussion
The effectiveness and safety of methotrexate therapy in patients with and without psoriatic arthritis were compared in a prospective, single-arm, interventional study. Significantly more patients with psoriatic arthritis presented with diabetes at baseline. Similar findings have been reported by Coto-Segura et al, 14 and increased levels of adipokines that drive insulin resistance in patients with psoriatic arthritis may provide an explanation for this observation. 15 Our results demonstrated that 50% of patients without and 41% of patients with psoriatic arthritis achieved PASI75 responses after 12 weeks, which concurs with the findings reported by Boehncke and Schön. 16 Other investigators have reported that the PASI75 response rate can vary from 24% to 73% during 12 to 24 weeks, 17-24 depending on the methotrexate dose, the time when the response is measured, and the study's design. Statistical differences in PASI90 response at weeks 8 and 12 were observed between patients with and without psoriatic arthritis, which can be better explained by the fact that psoriatic arthritis occurs later in psoriasis and a longstanding disease may be harder to control.
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More patients with psoriatic arthritis reported dizziness and nausea or vomiting compared with patients without psoriatic arthritis. This difference might also be related to genetic factors.
26 Sampaio-Barros et al 27 described 8.8% of patients with ankylosing spondylitis receiving methotrexate treatment who reported dizziness, which is consistent with 9.4% of patients with psoriatic arthritis in our study who also experienced dizziness. Overall, 105 patients (44.7%) reported methotrexate-associated adverse events, which were mostly mild or moderate, and none of the patients dropped out of the study because of severe adverse events. Methotrexate-associated abnormal hepatic function was observed in 61 patients (26.0%), which was similar to previously reported incidence rates of 15% to 50%. 20 Moreover, abnormal hepatic function was more severe in patients with psoriatic arthritis than in those without psoriatic arthritis. Smoking and increased BMI are important risk factors in patients with psoriasis with ALT level elevations. Associated with significantly lower methotrexate polyglutamate 3 concentrations in red blood cells, smoking increases the basal metabolic rate in patients with rheumatoid arthritis and may affect drug metabolism. 28 No difference in the percentage of smoking was observed between patients with vs without psoriatic arthritis, but the mean BMI was higher in those with vs without psoriatic arthritis, which might be one reason why methotrexate-induced liver enzyme elevations were more frequent in patients with psoriatic arthritis. A previous study 29 also reported that obesity and diabetes were significant risk factors for liver injury, which is consistent with our observation. However, the mechanism of hepatotoxicity remains to be elucidated. Methotrexate-associated myelosuppression was similar in patients with and without psoriatic arthritis. The lack of use of concomitant folic acid might be related to the hematologic laboratory changes observed in this study. However, the rate of cytopenia (2.6%) was similar to previously reported methotrexate-related myelosuppression rates of 2% to 10.2%. 30, 31 Mean corpuscular volume elevations and hemoglobin level decreases have been ascribed to the inhibition of folic metabolism during methotrexate therapy. 32 The increase in neutrophils induced by methotrexate in patients without psoriatic arthritis might be associated with infection. Monocyte levels increased significantly after methotrexate treatment, but the mechanism is unclear
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; methotrexate has previously been reported to act as a strong differentiation factor for immature and undifferentiated monocytic cells in vitro. 34 Furthermore, methotrexate treatment boosts systemic monocyte generation. 35 Additional studies are needed to identify the stimulatory factors involved in this process.
Limitations
The limitations of this study are its short intervention course (12 weeks) and its single-center setting. Gastrointestinal tract adverse events might have been overestimated because no folic acid supplementation was prescribed.
Conclusions
Our study demonstrated that methotrexate was well tolerated by Chinese outpatients with psoriasis. Methotrexate appeared to be more effective and had fewer adverse effects in patients without psoriatic arthritis compared with those with psoriatic arthritis. Although multicenter trials with larger sample size are needed to confirm these results, our findings suggest that methotrexate can be recommended as first-line treatment for psoriasis without arthritis.
